baber/WOPTO huggingface dataset:
Patent NZ-589433-A (NZ)
Title: Low density ammonium nitrate fuel oil (ANFO) emulsion
Inventor: PEREZ CORDOVA PIO FRANCISCO
IPC: C06B31/28
Filed: 2010-11-22
Abstract: A non-explosive emulsion having a density between 1.30 g/cm3 and 1.40 g/cm3 that is selectively activated by a gas-producing agent resulting in an explosive emulsion having a density between 0.5 g/cm3 and 0.90 g/cm3. The non-explosive emulsion consists essentially of between 84 percent and 95 percent by weight of an oxidizing solution and between 5 percent and 16 percent by weight of a fuel solution. The fuel solution includes steric acid to prevent the combination of the resulting nitrogen bubbles The oxidising solution consists of: 60-80 percent by weight of ammonium nitrate, 2-16 percent by weight of sodium nitrate, 0.1-2 percent by weight of thiourea, 14-22 percent by weight of water and 2-12 percent by weight of urea. The fuel solution consists of: 10-30 percent by weight of an emulsifier, 10-40 percent by weight of oil, 10-70 percent by weight of diesel No. 2 fuel, 0.1-10 percent by weight of solid cacao fat and 0.1-30 percent by weight of stearic acid.
Patent NZ-591543-A (NZ)
Title: Improved antibody libraries
Inventor: HSIEH CHUNG-MING
IPC: C07H21/04
Filed: 2009-09-30
Abstract: Disclosed are in vitro RNA display libraries to allow reliable expression and selection of scFv antibody molecules from expression libraries. The scFv antibody libraries of the invention contain an optimized, shortened inter-domain linker that improves expression scFv antibody expression. The scFv antibody libraries also include short nucleic acid barcodes that allow for identification of individual library clones, libraries or subsets thereof. Primers for generating, amplifying and spectratyping the scFv antibody libraries of the invention are also provided.
Patent NZ-591717-A (NZ)
Title: Method for eliminating leafstalks from a harvested stream using gaps which retain stalks but not berries
Inventor: DEFURNE CHRISTOPHE R
IPC: A01D46/28
Filed: 2009-10-09
Abstract: 591717 Disclosed is a method for eliminating leafstalks (P) from a harvested stream in a berry (G) harvesting machine, and a machine which uses such a method. The method comprises successively the steps of disposing at least a portion of the stream containing leafstalks (P) and berries (G) on a continuous conveyor belt (5) in a longitudinal direction (L2); disposing the portion on a discontinuous conveyor belt (6) longitudinally aligned with the continuous belt, the discontinuous belt having vertical (7) openings with a geometry that is configured for enabling berries (G) to pass through them and to retain leafstalks (P) on the discontinuous belt; eliminating leafstalks (P) remaining on the discontinuous belt.
Patent NZ-592566-A (NZ)
Title: 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission
Inventor: SONESSON CLAS
IPC: A61K31/40
Filed: 2009-11-24
Abstract: 592566 Disclosed are 3-phenyl-3-methoxy-pyrrolidine derivative of Formula 1 where the substituents are as disclosed in the specification. Examples of compounds of formula (I) are: (+)-3-(3-Chloro-2-fluorophenyl)-3-methoxypyrrolidine; (+)-3-(3-Chloro-2-fluorophenyl)-1-ethyl-3-methoxypyrrolidine 3-(3,4-Difluorophenyl)-(1-D)-3-methoxypyrrolidin Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and the use of compounds of formula (I) in the manufacture of medicaments for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to modulation of catecholamines in the cerebral cortex.
Patent NZ-595522-A (NZ)
Title: Method of radio-sensitizing tumors using a radio-sensitizing agent
Inventor: DIEBOLD JAMES L
IPC: A61K31/00
Filed: 2007-11-20
Abstract: ABSTRACT - 595522 The disclosure relates to a pharmaceutical composition for radiosensitizing cancer cells comprising a radiosensitizing amount of a compound of formula (I), or a pharmaceutically acceptable salt form thereof, wherein X is a prodrug moiety selected from the group defined in the specification (preferably said radiosensitizing compound of formula (I) is 7-methoxy-5-(4-methyl-piperazin-1-ylmethyl)-1,2,3,11-tetrahydro-5,11-diazabenzo[a]trindene-4,6-dione, 7-methoxy-5-(diethylaminomethyl)-1,2,3,11-tetrahydro-5,11-diaza-benzo[a]trindene-4,6-dione, 7-meth oxy-5,11-(bis-diethylaminomethy 1)-1,2,3,11-tetrahydro-5,11-diazabenzo[a]trindene-4,6-dione or 7-methoxy-5,11-(bis-morpholin-4-ylmethyl)-1,2,3,11-tetrahydro-5,11-diaza-benzo[a]trindene-4,6-dione), and a pharmaceutically acceptable carrier.
Patent NZ-597117-A (NZ)
Title: Screening method for cell aging
Inventor: MELLOR ELIZABETH JANE
IPC: G01N33/50
Filed: 2010-07-08
Abstract: Disclosed is an in vitro method for increasing the chronological lifespan of a cell, wherein said cell is not a human totipotent stem cell, comprising disrupting the function of the SAGA complex in said cell, wherein the complex is disrupted by disrupting the function of the Spt7 gene or homologue. Also disclosed is an in vitro method for identifying a potential modulator of the chronological life span (CLS) of a cell, comprising the steps of: contacting a cell, wherein said cell is not a human totipotent stem cell, having a known Histone 3 Lysine 18 (H3K18) acetylation status with a test compound; and determining if said compound has an effect on the acetylation status of H3K18 in said cell; wherein a change in the acetylation status of H3K18 in the cell indicates that the compound modulates CLS. Further disclosed is an in vitro method of identifying a change in the chronological life span (CLS) of a cell, wherein said cell is not a human totipotent stem cell, comprising identifying the acetylation state of H3K18 in the cell and comparing this to the acetylation state of a control cell, wherein loss of H3K18Ac when compared to the control cell indicates a reduced CLS and acquisition of H3K18Ac indicates an increased CLS.
Patent NZ-598028-A (NZ)
Title: Corneal and epithelial remodelling
Inventor: CHOO JENNIFER DENISE
IPC: A61F9/00
Filed: 2007-07-31
Abstract: 598028 An orthokeratology contact lens is disclosed which assists in preventing the progression of myopia. The posterior surface of the lens is adapted to be placed in contact with the cornea of a wearer's eye and worn over a period of time to reshape the cornea. The posterior surface of the lens comprises a central treatment zone adapted to overlie a central optical region of the eye, an annular peripheral treatment zone which is contiguous with the central treatment zone and which is adapted to overlie a peripheral optical region of the eye and an annular centration zone which is contiguous with and surrounds the peripheral treatment zone. The centration zone is shaped to approximate the configuration of the eye in a region of the eye radially outwards of the peripheral optical region. The central treatment zone is adapted to shape the central optical region of the cornea to result in axial light entering the eye being focused on or about the retina of the wearer. The peripheral treatment zone is adapted to shape the peripheral optical region of the eye into a configuration which will result in peripheral light entering the eye being focused at a location anterior of the retina of the wearer.
Patent NZ-598962-A (NZ)
Title: Coiled coil and/or tether containing protein complexes and uses thereof
Inventor: CHRISTENSEN ERIN H
IPC: C12P21/02
Filed: 2010-09-16
Abstract: Disclosed is an antibody comprising: (a) a first polypeptide comprising a VH domain linked to a constant domain and a first coiled coil domain (CC), wherein the first CC comprises a heptad repeat of Formula I: (X1 X2 X3 X4 X5 X6 X7)n (Formula I) (SEQ ID NO: 29) X1 is a hydrophobic amino acid residue or Asparagine, X2, X3, and X6 are each any amino acid residue, X4 is a hydrophobic amino acid residue, and X5 and X7 are each a charged amino acid residue; and (b) a second polypeptide comprising a VH domain linked to a constant domain and a second coiled coil domain (CC), wherein the second CC comprises a heptad repeat of Formula II: (X’1 X’2 X’3 X’4 X’5 X’6 X’7)n (Formula II) (SEQ ID NO: 30) X’1 is a hydrophobic amino acid residue or Asparagine, X’2, X’3, and X’6 are each any amino acid residue, X’4 is a hydrophobic amino acid residue, and X’5 and X’7 are each a charged amino acid residue; wherein n in Formula I and II is greater than or equal to 2; and wherein, in each heptad repeat, the first CC comprises an X5 residue that is opposite in charge to the X’7 residue in the second CC and the first CC comprises an X7 residue that is opposite in charge to the X’5 residue in the second CC, wherein the CC is linked to the constant domain by a linker and wherein the linker is cleavable.
Patent NZ-601001-A (NZ)
Title: Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
Inventor: PETERSSON KARSTEN
IPC: A61P17/10
Filed: 2010-12-22
Abstract: A storage stable, substantially anhydrous topical, pharmaceutical composition comprising: calcipotriol in dissolved form; a solvent mixture consisting essentially of a fatty acid ester solvent selected from the group consisting of glyceryl esters, isopropyl esters of C10-18 alkanoic or alkenoic acids, or propylene glycol esters, or mixtures thereof; a fatty alkyl ether co-solvent which is a compound of general formula H(OCH2C(R2)H)xR1, wherein R1 is straight or branched chain C1-20 alkyl, each R2 is individually hydrogen or CH3, and x is an integer of 2-60; and a lipophilic penetration enhancer selected from the group consisting of N-alkylpiperidone, N-alkylpyrrolidone, dimethylacetamide, dimethylsulfoxide or 2-pyrrolidone; and a substantially anhydrous carrier. the composition may be used in the treatment of dermatological disease or condition such as psoriasis, pustulosis palmoplantaris, ichtyosis, rosacea, dermatitis and acne.
Patent NZ-602341-A (NZ)
Title: Hybrid polypeptides with selectable properties
Inventor: LEVY ODILE ESTHER
IPC: C07K14/47
Filed: 2005-02-11
Abstract: 602341 Discloses a hybrid polypeptide exhibit at least one hormonal activity, where the peptide comprises a first bio-active peptide molecule covalently linked to at least one additional bio-active peptide molecule, wherein the two peptide molecules are Peptide YY (PYY) and exendin-4. Also discloses the use of the peptide in the treatment of metabolic diseases such as diabetes, insulin-resistance and obesity.
Patent NZ-603176-A (NZ)
Title: Low-oil pharmaceutical emulsion compositions comprising progestogen
Inventor: PICKERSGILL LAURA
IPC: A61K9/00
Filed: 2011-04-26
Abstract: Patent No. 603176 Disclosed is a sterile, ready-to-use, pharmaceutical oil-in-water emulsion composition for parenteral administration comprising: • 0.015 to 0.5% wt/vol, preferably 0.05 to 0.4% wt/vol progesterone; • 0.5 to 10% wt/vol of oil, wherein the oil comprises at least 85% wt/wt triglyceride; • 0.0425 to 4.1% wt/vol, preferably 0.064 to 3.4% wt/vol of phospholipid; • 80-99.4% wt/vol aqueous medium; wherein the composition has an osmolality in the range of 200-1000 mOsm/kg, and wherein the emulsion contains no more than 1.2% wt/wt of polyethylene glycol 15-hydroxystearate.
Patent NZ-603346-A (NZ)
Title: Povidone iodine, a novel alternative preservative for ophthalmic compositions
Inventor: LIANG BO
IPC: A01N45/00
Filed: 2009-06-10
Abstract: The disclosure relates to a preserved ophthalmic preparation comprising: (a) povidone-iodine (PVP-I) at a concentration sufficient to preserve said preparation, and (b) at least one non-steroidal anti-inflammatory compound selected from the group consisting of nepafenac and bromfenac; wherein said preparation may further comprises an antimicrobial preservative selected from the group consisting of benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, EDTA, sorbic acid, Onamer M and any combination thereof, and wherein said preparation may further comprise a viscosity increasing agent is selected from the group consisting of polyvinyl alcohol, polyvinylpyrrolidone, methyl cellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, carboxymethylcellulose, hydroxypropylcellulose, and any combination thereof.
Patent NZ-604087-A (NZ)
Title: Processes and intermediates for the preparation of protease inhibitors
Inventor: CHEN MINZHANG
IPC: C07D209/52
Filed: 2006-08-18
Abstract: Disclosed are t-butyl octahydrocyclopenta[c]pyrrole derivatives of formula (1a) e.g. (1S,3aR,6aS)-t-butyl 2-((S)-2-((S)-2-(benzyloxycarbonylamino)-2-cyclohexylacetamido)-3,3-dimethylbutanoyl)octahydrocyclopenta[c]pyrrole-1-carboxylate, wherein the variables are defined in the specification.
Patent NZ-618096-A (NZ)
Title: Roadside barrier post attachment
Inventor: COLQUHOUN TERRY
IPC: E01F15/04
Filed: 2012-05-16
Abstract: A roadway, guard rail or safety barrier having a post and beam construction is disclosed. The beam is mounted to the post by means of a carriage (71.070) and the beam is secured to the carriage (71.070) by a securement means. The carriage (71.070) is adapted to travel longitudinally relative to the post in the event of a collision. The post further includes at least one carriage support means (71.192, 71.292) and one or more engagement means (71.090) on an outer face of the post. The engagement means (71.090) engages the securement means (71.090) to provide resistance to movement of the carriage (71.070) with respect to the post where the carriage (71.070) is sized and shaped so as to not engage or to minimise engagement with the engagement means (71.090) during the movement.
Patent NZ-619935-A (NZ)
Title: Drag and drop of objects between applications
Inventor: URBACH JULIAN MICHAEL
IPC: G06F17/00
Filed: 2012-08-10
Abstract: Methods and systems directed to capturing an object (303a) rendered on the first window (V1) of a display by a first program, extracting the object (303a), permitting a user to drag the object (303a) across the display into a second window (V2) of the display containing a second program, and importing the object (303d) into the second program in substantially real-time. The drag and drop from a first window (V1) to a second window (V2) comprises rendering a borderless window and a selection (306) in the borderless window. The selection (306) comprises the object (303a) select by the user. The borderless window is then moved from the first window (V1) to the second window (V2). The drag and drop process occurs seamlessly to the user and permits a user to select one or more of a plurality of objects in one application, drag the object into a second application for modification, and drag the modified object back into the first application for real-time preview.
Patent NZ-625342-A (NZ)
Title: 2’,4’-difluoro-2’-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
Inventor: ZHANG JING
IPC: C07H19/06
Filed: 2012-12-17
Abstract: Provided are 2’,4’-difluoro-2’-methyl substituted nucleoside phosphoramidate derivative compounds of the general formula I, where the variables are as defined in the specification. Examples of the compounds include (S)-2-{ [(2S,3S,4R,SR)-S-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-2,4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-phenoxyphosphorylamino} -propionic acid isopropyl ester and (S)-2-[[(2S,3S,4R,SR)-S-(S-bromo-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-2,4-difluoro-3-hydroxy-4-methyl-tetrahydro-furan-2-ylmethoxy]-(naphthalen-2-yloxy)-phosphorylamino]-propionic acid isopropyl ester. The compounds are inhibitors of hepatitis C virus (HCV) RNA replication.
Patent NZ-627861-A (NZ)
Title: Self-preserved oil dispersions comprising boric
Inventor: GARRIGUE JEAN-SÉBASTIEN
IPC: A61K47/44
Filed: 2013-02-22
Abstract: The present disclosure relates to a self-preserved oil dispersion. Especially, the present disclosure relates to a self-preserved oil dispersion including a dispersed oil phase, an aqueous phase and at least one surfactant, wherein said oil dispersion comprises boric acid in an amount ranging from 0.005% to 0.075% in weight of the total weight of the oil dispersion, said amount of boric acid being a preservative effective amount so that the oil dispersion has a preservative activity.
Patent NZ-628054-A (NZ)
Title: Treatment of addiction and impulse-control disorders using pde7 inhibitors
Inventor: DEMOPULOS GREGORY A
IPC: A61P25/36
Filed: 2011-11-07
Abstract: Disclosed is the use of a selective phosphodiesterase 7 (PDE7) inhibitory agent in the manufacture of a medicament for treating or reducing the likelihood of an addiction that is a compulsive behaviour associated with a primary impulse-control disorder or an obsessive-compulsive disorder, wherein a subject is determined to be at risk of developing an addiction and is administered an amount of an inhibitor of the PDE7 inhibitory agent effective for the treatment or reduced likelihood of the addiction, and wherein the PDE7 inhibitory agent is a selective PDE7 inhibitor for which the lesser of the IC50 for inhibiting PDE7A activity and the IC50 for inhibiting PDE7B activity is less than one tenth the IC50 that the agent has for inhibiting the activity of all other PDE enzymes from the PDE1-6 and PDE8-11 enzyme families.
Patent NZ-701654-A (NZ)
Title: Weld stress compensation system
Inventor: UECKER TIMOTHY M
IPC: B23K37/053
Filed: 2013-05-14
Abstract: Weld stress compensation system and method comprising: 1) a primary tube/rod clamp; 2) a secondary tube/rod clamp for selectively and accurately, angularly positioning the secondary tube relative to the primary tube. The secondary clamp is transferrable while a secondary tube/rod is clamped therein to: 3) a saddle cutting fixture to produce a concave, relieved portion in the end of the secondary tube/rod with flanking flanges that fit precisely over the primary tube at the join intersection; 4) a miter-cut fixture for miter cutting of tube/rod ends to fit flat surfaces or conversely-cut tubes/rods for angular joins; and 5) a welding fixture for precise angular positioning of a miter cut tube/rod to a deck, wall, or stair plate. The primary clamp includes an adjustable pressure pad that applies pressure to the side of the primary tube opposite the secondary tube weld join line thereby preventing warping due to weld stresses.
Patent NZ-702152-A (NZ)
Title: Sock with gaiter integrally formed
Inventor: PINTO RODRIGUES PAULO JORGE
IPC: A41B11/00
Filed: 2013-04-22
Abstract: Sock and gaiter knitted integrally in a single garment. The sock comprises a legging (1) and a foot of the sock (3). Coupled to the sock, there is a gaiter (2) along the sock circular section, between said legging (1) and said foot (3). The sock and gaiter (2) are integrally formed as from a single piece of circular section, by joining with each other two circular sections of the single piece so as to form the gaiter (2) from the portion of material between the said two circular sections. The sock and gaiter includes adjusting gripping means (4).
Patent NZ-707113-A (NZ)
Title: Compositions comprising peroxy acid
Inventor: NEAS EDWIN D
IPC: C07C409/24
Filed: 2013-10-18
Abstract: The present invention provides methods for producing a non α-keto peracid that has lower toxicity and lower corrosivity. The present embodiments also provide methods and compositions for reducing microbes on a surface, methods and compositions for preventing and reducing infectious vegetative bacteria on a substrate, and methods and compositions for treating a wound. In particular, compositions of the invention provide for a mixture of an α-keto peracid and a non α-keto peracid that works synergistically to reduce microbes on a surface, to prevent vegetative bacteria on a surface and to heal a wound in animals or humans.
Patent NZ-710652-A (NZ)
Title: Method and system for saccharifying and fermenting a biomass feedstock
Inventor: MEDOFF MARSHALL
IPC: C12P7/14
Filed: 2010-11-18
Abstract: Discloses a method comprising: placing a liquid medium comprising electron beam irradiated lignocellulosic feedstock in a vessel; and saccharifying the feedstock in the vessel, while mixing with a jet mixer, to obtain a sugar solution having a final concentration of glucose of at least 15% by weight.
Patent NZ-711636-A (NZ)
Title: Novel diagnostic method for diagnosing depression and monitoring therapy effectiveness
Inventor: ARNOLDUSSEN EDUARD ANTONIUS JOANNES
IPC: A61B5/16
Filed: 2014-01-31
Abstract: Many factors appear to play a role or contribute to the development of mood disorders, especially depression and more particularly major depression disorder (MDD). The present invention provides a panel of biomarkers for the diagnosis and monitoring of depression, where this panel comprises biomarkers that are complementary as regards to the (putative) role they are playing in the ontogenesis of depression. Specifically, the present invention provides a method for the diagnosis of a mood disorder or predisposition for a mood disorder in an individual, by: a. measuring the concentration of a total of six or more biomarkers, which total of six or more biomarkers is selected from the groups of urine biomarkers and serum biomarkers, which groups consist of: • Urine biomarkers: cortisol, Substance P, cAMP, aldosteron, lipocalin, LTB4, TNF alpha receptor 2, HVEM, thromboxane B2, F2-isoprostane, midkine, endothelin-1, c-GMP, pregnenolone, EGF, calprotectin, leptin, neuropeptide Y, and adiponectin, when measured in a urine sample previously obtained from said individual; and • Serum biomarkers: zonulin, cAMP, aldosteron, lipocalin, TNF alpha receptor 2, HVEM, thromboxane B2, nitrotyrosine, F2-isoprostane, BDNF, midkine, endothelin-1, vitamin D, substance P, EGF, calprotectin, leptin, AVP (vasopressine), neuropeptide Y, LTB4, and cortisol, when measured in a blood, serum or plasma sample previously obtained from said individual, b. comparing said concentration with the concentration of said six or more biomarkers in a control healthy subject; c. diagnosing the mood disorder if the concentration is deviant from the concentration in control healthy subjects, wherein the mood disorder is depression, chosen from dysthymia, endogenous depression, reactive depression, minor depression, major depression, psychotic depression, neurotic depression, postnatal depression, burn out, overstrain, unipolar depression and bipolar depression.
Patent NZ-718495-A (NZ)
Title: Inhalable pharmaceutical compositions comprising coenzyme q10
Inventor: NARAIN NIVEN RAJIN
IPC: A61K47/24
Filed: 2012-06-18
Abstract: Inhalable pharmaceutical compositions can include an aqueous dispersion of particles including a hydrophobic bioactive agent (e.g., CoQ10) suitable for continuous aerosolization. Due to their chemical composition and methods of manufacture, the pharmaceutical compositions exhibit distinctive physicochemical properties that provide advantageous aerosol transmission and output. the compositions comprises: a dispersion of liposomal particles having an average diameter between about 30 and 500 nm, each liposomal particle comprising a hydrophobic bioactive agent, a phospholipid, and an aqueous dispersion vehicle, wherein the ratio of hydrophobic bioactive agent phospholipid is between about 5:1 and about 1:5, the hydrophobic bioactive agent is between about 0.1 and 30 % w/w of the composition, the phospholipid is between about 0.1 and 30 % w/w of the composition, and the liposomal particles are dispersed within the aqueous dispersion vehicle
Patent NZ-720868-A (NZ)
Title: A chromone derivative as a dopamine d3 receptor antagonist for its use for the treatment of autism spectrum disorder
Inventor: SOKOLOFF PIERRE
IPC: A61K31/55
Filed: 2014-12-12
Abstract: The present invention claims a chromone derivative and pharmaceutical compositions and combinations comprising at least the said derivative, which is a dopamine D3 receptor antagonist, for their use for the treatment of the social interaction deficits associated to autism spectrum disorder.